May 21, 2020
LEMONAID takes on the challenge of developing a new drug against Diffuse Large B-Cell Lymphoma (DLBCL) tumors to ultimately reduce drug resistance and relapse potential for patients. InnoSer supports this ambition by its expertise in combined in-vitro and in-vivo...
Apr 30, 2020
Organized by flanders.bio since it’s establishment in 2004, knowledge for growth brings over 1300 biotech, pharma, medtech, agricultural and chemical industry experts and decision makers, as well as investors, universities, topnotch research institutes,...
Apr 13, 2020
As of April 2020, Wim Tiest has joined InnoSer in the role of Chief Technology Officer (CTO) and as part of the company management team. Wim holds a MSc in biochemical engineering and in artificial intelligence, both from the KU Leuven. He has built his professional...
Apr 7, 2020
Despite the challenging times for the life sciences sector during coronavirus restrictions, we’ve been fortunate enough and well prepared to continue with the development of our PDX/O platform for oncology research. On a weekly basis we receive patient tumor samples...
Mar 20, 2020
Press release | Leiden, 19 March 2020 InnoSer continues to deliver critical in-vivo and in-vitro services COVID-19 restrictions call for attention to prevent fully halting life sciences operations InnoSer remains committed to continuing its in-vivo and in-vitro...
This website uses cookies to improve your experience. Information about your use of the site is also shared with Google for analyzing traffic to this site. You can opt-out if you wish. Cookie settingsACCEPT Privacy policy Privacy & Cookies Policy
Recent Comments